PMID: 8593713Sep 1, 1995Paper

Nail incorporation kinetics of terbinafine in onychomycosis patients

Clinical and Experimental Dermatology
F SchatzA Stütz

Abstract

Patients with toe-nail onychomycosis were treated with terbinafine (250 mg daily, n = 20) for either 6 or 12 weeks in a randomized double-blind study. Plasma and distal nail clippings were taken before initiation of therapy and 1, 6, 12, 18, 24, 36 and 48 weeks thereafter. Analytical data of terbinafine extracted from nail clippings or plasma were obtained by high-performance liquid chromatography (HPLC). Nail extracts and isolated HPLC terbinafine peaks were analysed using a combined gas chromatography-mass spectroscopy system (GC-MS) for unequivocal identification of the drug. Terbinafine could be detected in the distal nail in the majority of the patients within 1 week of starting therapy. Maximum terbinafine levels of 0.52 and 1.01 micrograms/g were measured after 18 weeks in the 6- and 12-week treatment groups, respectively. While plasma levels decreased rapidly after termination of therapy terbinafine was detected in the nails as long as 30 weeks (6 weeks treatment) and 36 weeks (12 weeks treatment) after termination of therapy at a range of 0.28-0.19 microgram/g. The drug concentrations measured at all time points are well above the minimum inhibitory concentration (MIC) for dermatophytes and other fungi. These data sugg...Continue Reading

References

Feb 1, 1992·The British Journal of Dermatology·A Y Finlay
Feb 1, 1992·The British Journal of Dermatology·V V Villars, T C Jones
Jan 1, 1992·Current Topics in Medical Mycology·N S Ryder, H Mieth
Sep 1, 1987·Antimicrobial Agents and Chemotherapy·G PetranyiH Mieth

❮ Previous
Next ❯

Citations

Dec 19, 2001·Biomedical Chromatography : BMC·J KuznerM Drobnic-Kosorok
Dec 20, 2002·Clinics in Dermatology·Joseph Obadiah, Richard Scher
Oct 9, 1999·International Journal of Dermatology·P De Doncker
Oct 9, 1999·International Journal of Dermatology·A K Gupta, J Lambert
Jan 29, 2000·International Journal of Dermatology·S Jain, V N Sehgal
Aug 16, 2000·International Journal of Dermatology·S Jain, V N Sehgal
Feb 27, 1999·The Pediatric Infectious Disease Journal·K C Hazen, G Wu
Jul 28, 2001·Clinical Pharmacokinetics·D Debruyne, A Coquerel
Nov 3, 2007·Nihon Ishinkin Gakkai zasshi = Japanese journal of medical mycology·Hideomi Shibaki
Aug 10, 2012·Drug Development and Industrial Pharmacy·Xiaoying HuiHoward I Maibach
Aug 11, 2012·Expert Opinion on Investigational Drugs·Bárdur Sigurgeirsson, Mahmoud Ghannoum
Jan 26, 2007·Advances in Dermatology·Daniel S Loo
Nov 12, 2005·Skinmed·Aditya K GuptaElizabeth A Cooper
May 29, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·A K GuptaA Tavakkol
Jan 7, 1998·Journal of the American Academy of Dermatology·A K Gupta, N H Shear
Oct 4, 2005·Journal of the American Academy of Dermatology·Erin M WarshawFrank A Lederle
Mar 11, 1998·Lancet·A K Gupta, R K Scher
Sep 6, 2003·Dermatologic Clinics·Aditya K Gupta, Jennifer E Ryder
Jul 28, 1999·Annales de dermatologie et de vénéréologie·C Viguié-Vallanet
Sep 17, 2004·The Journal of Dermatological Treatment·F PavlotskyH Trau
Aug 19, 2005·Expert Review of Anti-infective Therapy·Adolfo C Fernandez-ObregonCarolyn Willis
Mar 24, 2000·The British Journal of Dermatology·D T Roberts
Jun 9, 2004·International Journal of Cancer. Journal International Du Cancer·Pei-Yin HoWen-Sen Lee
Jul 15, 2017·The Cochrane Database of Systematic Reviews·Sanne Kreijkamp-KaspersMieke L van Driel
Jun 7, 2005·Expert Opinion on Pharmacotherapy·Robert BaranGerald E Piérard
Sep 22, 2005·Therapeutic Drug Monitoring·Ingrid CastbergTrond O Aamo
Jan 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·A K Gupta, N H Shear
Apr 3, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·Aditya K GuptaBianca Maria Piraccini
Dec 20, 2012·Psychiatry Investigation·Young-Min Park
Dec 13, 2002·American Journal of Clinical Dermatology·Malcolm J M DarkesKaren L Goa
Sep 7, 2000·Medical Mycology·A K Gupta, R C Summerbell
Sep 7, 2019·Journal of Fungi·Anarosa B SprengerFlávio Queiroz-Telles
May 25, 2021·The Journal of Dermatology·Hiromitsu NoguchiSatoshi Fukushima

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.